3D engineering for optic neuropathy treatment
Copyright © 2020 Elsevier Ltd. All rights reserved..
Ocular disorders, such as age-related macular degeneration (AMD), diabetic retinopathy (DR), retinitis pigmentosa (RP), and glaucoma, can cause irreversible visual loss, and affect the quality of life of millions of patients. However, only very few 3D systems can mimic human ocular pathophysiology, especially the retinal degenerative diseases, which involve the loss of retinal ganglion cells (RGCs), photoreceptors, or retinal pigment epithelial cells (RPEs). In this review, we discuss current progress in the 3D modeling of ocular tissues, and review the use of the aforementioned technologies for optic neuropathy treatment according to the categories of associated disease models and their applications in drug screening, mechanism studies, and cell and gene therapies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Drug discovery today - 26(2021), 1 vom: 16. Jan., Seite 181-188 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xuan, Wenjing [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 17.12.2021 Date Revised 02.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.drudis.2020.09.034 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316084271 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316084271 | ||
| 003 | DE-627 | ||
| 005 | 20231225160320.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.drudis.2020.09.034 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM316084271 | ||
| 035 | |a (NLM)33038525 | ||
| 035 | |a (PII)S1359-6446(20)30394-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xuan, Wenjing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 3D engineering for optic neuropathy treatment |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.12.2021 | ||
| 500 | |a Date Revised 02.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Ocular disorders, such as age-related macular degeneration (AMD), diabetic retinopathy (DR), retinitis pigmentosa (RP), and glaucoma, can cause irreversible visual loss, and affect the quality of life of millions of patients. However, only very few 3D systems can mimic human ocular pathophysiology, especially the retinal degenerative diseases, which involve the loss of retinal ganglion cells (RGCs), photoreceptors, or retinal pigment epithelial cells (RPEs). In this review, we discuss current progress in the 3D modeling of ocular tissues, and review the use of the aforementioned technologies for optic neuropathy treatment according to the categories of associated disease models and their applications in drug screening, mechanism studies, and cell and gene therapies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Moothedathu, Aji Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Tuo |e verfasserin |4 aut | |
| 700 | 1 | |a Gibson, David C |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Jinhua |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Qingguo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug discovery today |d 1998 |g 26(2021), 1 vom: 16. Jan., Seite 181-188 |w (DE-627)NLM095449159 |x 1878-5832 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2021 |g number:1 |g day:16 |g month:01 |g pages:181-188 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.drudis.2020.09.034 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2021 |e 1 |b 16 |c 01 |h 181-188 | ||